Atara Biotherapeutics, Inc. (ATRA)

Atara Biotherapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Atara Biotherapeutics stock has a target of 6.00, which predicts a 41.18% increase from the current stock price of 4.25.

Price Target: $6.00 (+41.18%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	$6.00	$6.00	$6.00	$6.00
Change	+41.18%	+41.18%	+41.18%	+41.18%

* Price targets were last updated on Jan 13, 2026.

Analyst Ratings

According to 1 stock analyst, the rating for Atara Biotherapeutics is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Sep '25	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26
Strong Buy	2	2	2	2	0	0
Buy	1	1	1	0	0	0
Hold	2	2	2	1	2	1
Sell	0	0	0	0	0	0
Strong Sell	1	1	1	0	0	0
Total	6	6	6	3	2	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
John Newman Canaccord Genuity	Canaccord Genuity	Strong Buy → Hold Downgrades $25 → $6	Strong Buy → Hold	Downgrades	$25 → $6	+41.18%	Jan 13, 2026
John Newman Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $17 → $25	Strong Buy	Maintains	$17 → $25	+488.24%	Dec 19, 2025
John Newman Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $17	Strong Buy	Maintains	$17	+300.00%	Mar 11, 2025
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Jan 28, 2025
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Jan 22, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

123.67M

Decreased by -4.09%

from 128.94M

Revenue Next Year

59.10M

Decreased by -52.21%

from 123.67M

EPS This Year

2.14

from -11.41

EPS Next Year

0.08

Decreased by -96.42%

from 2.14

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	20.34M	63.57M	8.57M	128.94M	123.67M	59.10M
Revenue Growth	-	-	212.55%	-86.52%	1,404.02%	-4.09%	-52.21%
EPS	-103.63	-90.78	-55.96	-65.19	-11.41	2.14	0.08
EPS Growth	-	-	-	-	-	-	-96.42%
Forward PE	-	-	-	-	-	1.99	55.56
No. Analysts	-	-	-	-	-	6	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	130.2M	76.7M
Avg	123.7M	59.1M
Low	116.8M	43.3M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	1.0%	-38.0%
Avg	-4.1%	-52.2%
Low	-9.4%	-65.0%

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	2.59	0.91
Avg	2.14	0.08
Low	1.69	-0.71

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	-	-57.3%
Avg	-	-96.4%
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.